Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18650574 | ANTI-AGING STURGEON ROE TETRAPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOF | April 2024 | April 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18591918 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF | February 2024 | May 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18568888 | SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASES | December 2023 | May 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18385946 | CNP COMPOUNDS | November 2023 | May 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18491957 | INSECT NEUROPEPTIDES 1 | October 2023 | February 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18492076 | INSECT NEUROPEPTIDES 9 | October 2023 | October 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18473627 | BROWN FAT-SELECTIVE ADIPOKINES | September 2023 | April 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18457482 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOF | August 2023 | May 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18450524 | RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASES | August 2023 | June 2025 | Abandon | 22 | 1 | 1 | Yes | No |
| 18227782 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | July 2023 | July 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18360773 | COMPOSITION FOR IMPROVING MILD COGNITIVE IMPAIRMENT AND METHOD FOR IMPROVING MILD COGNITIVE IMPAIRMENT | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18348878 | PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEIN | July 2023 | September 2024 | Abandon | 14 | 1 | 0 | Yes | No |
| 18330109 | GROWTH PROMOTING PEPTIDES, AND USES THEREOF | June 2023 | August 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18203184 | ERYTHROPOIETIN AND ANALOGS FOR VETERINARY USE | May 2023 | August 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18318343 | COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE | May 2023 | May 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18301761 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS | April 2023 | January 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18180002 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | March 2023 | September 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18118113 | Skin Compositions and Uses | March 2023 | June 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18160787 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF | January 2023 | November 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 18157293 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | January 2023 | May 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18157307 | METHODS FOR PREVENTING AND TREATING INTRA-ABDOMINAL CANDIDIASIS | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18061699 | HISTATIN FOR CORNEAL WOUND HEALING AND OCULAR SURFACE DISEASE | December 2022 | December 2024 | Abandon | 24 | 1 | 1 | Yes | No |
| 18054587 | BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN | November 2022 | September 2024 | Abandon | 22 | 0 | 1 | Yes | No |
| 18053965 | PEPTIDE FOR TREATING SEPSIS DERIVED FROM RV3364C PROTEIN OF MYCOBACTERIUM TUBERCULOSIS | November 2022 | April 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 17981595 | SELF-ASSEMBLING ANTIVIRAL PRODRUGS | November 2022 | January 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18050604 | DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOF | October 2022 | March 2025 | Allow | 28 | 0 | 1 | Yes | No |
| 18050659 | DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOF | October 2022 | March 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 17921508 | FUSION POLYPEPTIDES FOR TARGET PEPTIDE PRODUCTION | October 2022 | July 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 17908853 | ANTIBACTERIAL PROTEIN HAVING LYTIC ACTIVITY TO BACILLUS GENUS AND METHOD FOR PREPARING THE SAME | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17898470 | NANO SMALL PEPTIDE AND ITS USE IN PREPARATION OF DRUGS FOR TREATING AND PREVENTING FUNDUS VASCULAR DISEASES | August 2022 | July 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17864486 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | July 2022 | August 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17756721 | ECHINOCANDIN ANALOGUES AND PREPARATION METHOD THEREFOR | June 2022 | April 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17747788 | COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF | May 2022 | June 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17741692 | POLYPEPTIDE, PHOTORESIST COMPOSITION INCLUDING THE SAME, AND METHOD OF FORMING PATTERN USING THE SAME | May 2022 | October 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17740202 | PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS | May 2022 | November 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17727579 | PTD-SMAD7 THERAPEUTICS | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17709731 | ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG | March 2022 | October 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17765342 | Muscle Tissue-Regenerating Agent | March 2022 | April 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17682277 | Novel Hybrid ActRIIB Ligand Trap Proteins for Treating Muscle Wasting Diseases | February 2022 | November 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17665179 | HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES | February 2022 | October 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17586774 | PEPTIDE FOR COMPLEXING ZINC ION, COMPLEX THEREOF AND USE THEREFOR | January 2022 | February 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17629999 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | January 2022 | April 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17579455 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS | January 2022 | August 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17627359 | ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION | January 2022 | December 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17574865 | ANTI-INFLAMMATORY PEPTIDES, AND USES THEREOF | January 2022 | May 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17566368 | METHOD FOR DECREASING IMMUNOGENICITY OF PROTEIN AND PEPTIDE | December 2021 | December 2023 | Abandon | 24 | 1 | 1 | Yes | No |
| 17621807 | PEPTIDE ACETALS FOR STABILISING ENZYMES | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17618117 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17546739 | PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEIN | December 2021 | December 2023 | Abandon | 24 | 2 | 1 | No | No |
| 17541145 | Compositions and Formulations and Methods of Production and Use Thereof | December 2021 | June 2024 | Abandon | 30 | 2 | 1 | Yes | No |
| 17538924 | OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMA | November 2021 | November 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17536296 | AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERS | November 2021 | December 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17535451 | TUMOR-SPECIFIC CLEAVABLE LINKERS | November 2021 | January 2025 | Allow | 38 | 1 | 2 | Yes | No |
| 17532978 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | November 2021 | August 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17532597 | METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE | November 2021 | March 2025 | Abandon | 39 | 3 | 1 | Yes | No |
| 17454931 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | November 2021 | November 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17609818 | PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B | November 2021 | August 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17512550 | Antithrombin-III Treatment of Traumatic Brain Injury | October 2021 | September 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17450613 | THERAPEUTIC METHOD OF TREATMENT FOR INHIBITING TUMOR DEVELOPMENT USING TAMM-HORSFALL GLYCOPROTEIN (THP) AS IMMUNOSTIMULATING DRUG AND COMPOSITIONS | October 2021 | March 2023 | Allow | 18 | 0 | 1 | No | No |
| 17493598 | RECOMBINANT ELASTIN AND PRODUCTION THEREOF | October 2021 | November 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17600468 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | September 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17599625 | Reagents and Assays using Modified Integrin Domains | September 2021 | December 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17487099 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION AND ASSOCIATED COAGULOPATHY | September 2021 | February 2025 | Abandon | 41 | 5 | 1 | Yes | No |
| 17598641 | SELF-ASSEMBLING 2D ARRAYS WITH DE NOVO PROTEIN BUILDING BLOCKS | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17442258 | SALT FORMS OF S-(N, N-DIETHYLCARBAMOYL)GLUTATHIONE | September 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17440527 | Peptide Inhibitors Targeting The CXCL12/HMGB1 Interaction And Uses Thereof | September 2021 | July 2024 | Allow | 34 | 0 | 1 | Yes | No |
| 17475451 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | September 2021 | December 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17475248 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | September 2021 | October 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17437025 | A PEPTIDE FOR THE DELIVERY OF ANIONIC MATERIALS | September 2021 | March 2024 | Allow | 30 | 0 | 0 | Yes | No |
| 17435215 | INHIBITION OF MYOSTATIN SIGNAL BY MYOSTATIN SPLICE VARIANT-DERIVED PROTEIN AND UTILIZATION THEREOF | August 2021 | October 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17433860 | PEPTIDES AND COMPOSITIONS FOR USE IN COSMETICS | August 2021 | October 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17310517 | NOVEL OCT-3/4 VARIANT | August 2021 | July 2024 | Allow | 35 | 1 | 0 | No | No |
| 17427109 | ANTI-ATOPIC DERMATITIS PROTEIN | July 2021 | December 2024 | Abandon | 41 | 3 | 1 | Yes | No |
| 17389064 | ANTIBACTERIAL COMPOSITION COMPRISING MICROCIN S AND ANTIBIOTIC | July 2021 | October 2023 | Abandon | 27 | 1 | 1 | Yes | No |
| 17425688 | NOVEL NON-OPIOID ANTI-PAIN MEDICATION | July 2021 | December 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17383597 | MASPIN, MASPIN DERIVATIVES, AND MASPIN MIMETICS FOR REDUCING ROS, INFLAMMATION, AND SKIN AGING | July 2021 | March 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17379987 | Mutant Peptides And Methods Of Treating Subjects Using The Same | July 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17423680 | POLYETHYLENE GLYCOL-MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17422935 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | July 2021 | September 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17422932 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CAIX | July 2021 | September 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17422718 | SERINE PROTEINASE INHIBITORS: SERP-1 AND SERP-1 RCL-DERIVED PEPTIDES EFFECT ON MICROBIOME COMPOSITION AND USES THEREOF | July 2021 | February 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17421477 | COMPOSITIONS CONTAINING A PEPTIDE ABLE TO STIMULATE THE GPRC6A-DEPENDENT SIGNALING PATHWAY | July 2021 | July 2024 | Abandon | 37 | 2 | 1 | Yes | No |
| 17420865 | HUMAN HEPATOCYTE GROWTH FACTOR MUTANT AND USES THEREOF | July 2021 | January 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17368065 | TMEM100 PEPTIDES AND VARIANTS THEREOF AND THEIR USE IN TREATING OR PREVENTING DISEASES OR CONDITIONS | July 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17364557 | Methods for Reducing Perinatal Morbidity and / or Mortality | June 2021 | March 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17420130 | COMPOSITION COMPRISING SERICIN FOR TREATING, PREVENTING, OR ALLEVIATING FATTY LIVER, AND METHOD OF PREPARING SAME | June 2021 | December 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17312806 | ANTIMICROBIAL PEPTIDES | June 2021 | December 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17332215 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOF | May 2021 | May 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17303250 | CYTOPLASMIC TRANSDUCTION PEPTIDE AND INTRACELLULAR MESSENGER COMPRISING SAME | May 2021 | June 2025 | Abandon | 49 | 3 | 1 | No | No |
| 17318198 | PRG-4 FOR TREATING GOUT AND ITS SYMPTOMS | May 2021 | September 2023 | Abandon | 28 | 1 | 1 | Yes | No |
| 17239934 | Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist | April 2021 | May 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17235485 | TOPICAL COMPOSITIONS FOR SKIN COMPRISING A CELL PENETRATING PEPTIDE AND METHODS OF USING THE SAME | April 2021 | May 2025 | Abandon | 49 | 5 | 1 | Yes | No |
| 17232891 | METHODS AND COMPOSITIONS FOR TREATING A RESPIRATORY DISEASE | April 2021 | October 2023 | Abandon | 30 | 1 | 1 | Yes | No |
| 17282872 | Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization | April 2021 | April 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17280058 | AMPHIPHILIC POLY (AMINO ACID), BLOCK COPOLYER USING THE AMPHIPHILIC POLY (AMINO ACID), AND COMPLEX INCLUDING THE AMPHIPHILIC POLY (AMINO ACID) OR THE BLOCK COPOLYMER AND NUCLEIC ACID | March 2021 | September 2024 | Allow | 41 | 0 | 1 | Yes | No |
| 17249175 | HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES | February 2021 | April 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17266939 | CELL-PENETRATING PEPTIDES | February 2021 | November 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17266811 | PEPTIDE HAVING ANTIOXIDANT ACTIVITY AND COMPOSITION CONTAINING SAME | February 2021 | November 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17165154 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | February 2021 | March 2025 | Abandon | 50 | 6 | 1 | Yes | Yes |
| 17165149 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | February 2021 | October 2023 | Abandon | 32 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOMATSU, LI N.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOMATSU, LI N works in Art Unit 1658 and has examined 409 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner KOMATSU, LI N's allowance rate of 53.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KOMATSU, LI N receive 1.77 office actions before reaching final disposition. This places the examiner in the 53% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KOMATSU, LI N is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +71.6% benefit to allowance rate for applications examined by KOMATSU, LI N. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.1% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 30.7% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 61.5% of appeals filed. This is in the 34% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 58.2% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 52% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 70% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.